“Would you be surprised?” Using the Surprise Question to Explore Medication Discontinuation
1 Study Overview
1.1 Background
The surprise question was developed over a decade ago and has been used in multiple settings to predict one year survival of different patient populations (e.g., to identify older hospitalized patients who may benefit from palliative or hospice care, to identify patients in the ED with a high risk of in-hospital mortality, predicting mortality for dialysis patients). The surprise question simply asks healthcare providers “would you be surprised if the patient died in the next 12 months?” No additional clinical data is needed. The predictive value of the surprise question has ranged from poor to reasonably accurate.
This quality improvement project would be to pilot the “surprise question” in select specialty clinics to assess its prognostic value in predicting patient outcomes. In Asthma and Allergy (ASAP) and Dermatology, pharmacists answered the question “Would you be surprised if this patient had a PDC of less than 90 or dose interruptions totaling 28 days or more over the next 6 months?”. In Oncology and Neurology, pharmacists answered the question “Would you be surprised if this patient discontinued this medication in the next 90 days?”
1.2 Methods
Quality Improvement Pilot.
2 Exclusions
| Characteristic | N | Overall N = 1,6111 |
ASAP N = 2921 |
Dermatology N = 3171 |
Neurology N = 2011 |
Oncology N = 8011 |
|---|---|---|---|---|---|---|
| Inclusion status | 1,611 | |||||
| Excluded | 304 (18.9%) | 57 (19.5%) | 64 (20.2%) | 25 (12.4%) | 158 (19.7%) | |
| Included | 1,307 (81.1%) | 235 (80.5%) | 253 (79.8%) | 176 (87.6%) | 643 (80.3%) | |
| Exclusion reason | 304 | |||||
| ASAP/Derm patients with <3 fills or with documented discontinuation | 41 (13.5%) | 18 (31.6%) | 23 (35.9%) | 0 (0%) | 0 (0%) | |
| Mediation had a finite duration known at therapy initiation | 66 (21.7%) | 0 (0%) | 1 (1.56%) | 0 (0%) | 65 (41.1%) | |
| Medically appropriate hold | 1 (0.33%) | 1 (1.75%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Medication dosed as needed | 5 (1.64%) | 5 (8.77%) | 0 (0%) | 0 (0%) | 0 (0%) | |
| Medication never started | 31 (10.2%) | 5 (8.77%) | 9 (14.1%) | 3 (12.0%) | 14 (8.86%) | |
| Prescription fill data was not available | 24 (7.89%) | 4 (7.02%) | 6 (9.38%) | 5 (20.0%) | 9 (5.70%) | |
| Surprise question not answered or duplicate | 136 (44.7%) | 24 (42.1%) | 25 (39.1%) | 17 (68.0%) | 70 (44.3%) | |
| 1 n (%) | ||||||
3 Demographics
Patient-medication level
| Characteristic | Overall N = 1,3071 |
ASAP N = 2351 |
Dermatology N = 2531 |
Neurology N = 1761 |
Oncology N = 6431 |
|---|---|---|---|---|---|
| Age at date counseled | |||||
| Mean (SD) | 55.7 (21.6) | 38.6 (25.8) | 46.5 (21.3) | 62.9 (18.6) | 63.6 (14.7) |
| Median (Q1, Q3) | 62.0 (41.9, 72.4) | 40.3 (12.2, 63.3) | 47.2 (29.9, 64.2) | 67.4 (55.9, 75.4) | 67.0 (55.4, 74.1) |
| Min, Max | 0.4, 92.3 | 0.5, 91.9 | 1.1, 92.3 | 0.4, 91.6 | 15.8, 92.1 |
| Sex | |||||
| Female | 633 (48.4%) | 146 (62.1%) | 154 (60.9%) | 75 (42.6%) | 258 (40.1%) |
| Male | 673 (51.5%) | 89 (37.9%) | 98 (38.7%) | 101 (57.4%) | 385 (59.9%) |
| Unknown | 1 (0.08%) | 0 (0%) | 1 (0.40%) | 0 (0%) | 0 (0%) |
| Race | |||||
| White | 1,040 (79.6%) | 168 (71.5%) | 182 (71.9%) | 140 (79.5%) | 550 (85.5%) |
| Black or African American | 166 (12.7%) | 41 (17.4%) | 39 (15.4%) | 23 (13.1%) | 63 (9.80%) |
| Other | 61 (4.67%) | 15 (6.38%) | 15 (5.93%) | 10 (5.68%) | 21 (3.27%) |
| Unknown | 40 (3.06%) | 11 (4.68%) | 17 (6.72%) | 3 (1.70%) | 9 (1.40%) |
| 1 n (%) | |||||
Patient level, but one patient represented twice Derm + Onc
| Characteristic | Overall N = 1,2291 |
ASAP N = 2341 |
Dermatology N = 2521 |
Neurology N = 1651 |
Oncology N = 5781 |
|---|---|---|---|---|---|
| Age at date counseled | |||||
| Mean (SD) | 55.2 (21.8) | 38.5 (25.7) | 46.6 (21.3) | 63.3 (18.4) | 63.4 (14.6) |
| Median (Q1, Q3) | 61.5 (41.5, 72.3) | 40.3 (12.2, 63.3) | 47.4 (30.2, 64.2) | 68.2 (55.4, 76.0) | 66.9 (55.1, 73.9) |
| Min, Max | 0.4, 92.3 | 0.5, 91.9 | 1.1, 92.3 | 0.4, 91.6 | 15.8, 92.1 |
| Sex | |||||
| Female | 611 (49.7%) | 146 (62.4%) | 153 (60.7%) | 71 (43.0%) | 241 (41.7%) |
| Male | 617 (50.2%) | 88 (37.6%) | 98 (38.9%) | 94 (57.0%) | 337 (58.3%) |
| Unknown | 1 (0.08%) | 0 (0%) | 1 (0.40%) | 0 (0%) | 0 (0%) |
| Race | |||||
| White | 970 (78.9%) | 167 (71.4%) | 181 (71.8%) | 130 (78.8%) | 492 (85.1%) |
| Black or African American | 159 (12.9%) | 41 (17.5%) | 39 (15.5%) | 22 (13.3%) | 57 (9.86%) |
| Other | 60 (4.88%) | 15 (6.41%) | 15 (5.95%) | 10 (6.06%) | 20 (3.46%) |
| Unknown | 40 (3.25%) | 11 (4.70%) | 17 (6.75%) | 3 (1.82%) | 9 (1.56%) |
| 1 n (%) | |||||
4 Background Information: Breakdown on Specialty medication by clinical area
4.1 Neurology
| Characteristic1 | N1 | N = 1761 |
|---|---|---|
| Medication | 176 | |
| Droxidopa | 48 (27.3%) | |
| Pimavanserin | 19 (10.8%) | |
| Edaravone | 16 (9.09%) | |
| Cannabidiol | 13 (7.39%) | |
| Riluzole | 11 (6.25%) | |
| Deutetrabenazine | 10 (5.68%) | |
| Tafamidis | 9 (5.11%) | |
| Valbenazine | 8 (4.55%) | |
| Acoramidis | 7 (3.98%) | |
| Eplontersen Sodium | 7 (3.98%) | |
| Amantadine | 6 (3.41%) | |
| Amantadine HCl ER | 6 (3.41%) | |
| Deutetrabenazine ER | 6 (3.41%) | |
| Tetrabenazine | 5 (2.84%) | |
| Istradefylline | 2 (1.14%) | |
| Vigabatrin | 2 (1.14%) | |
| Adalimumab | 1 (0.57%) | |
| 1 176 medications among 165 patients | ||
4.2 Oncology
| Characteristic1 | N1 | N = 6431 |
|---|---|---|
| Medication | 643 | |
| Relugolix | 119 (18.5%) | |
| Capecitabine | 40 (6.22%) | |
| Abiraterone Acetate | 37 (5.75%) | |
| Temozolomide | 33 (5.13%) | |
| Venetoclax | 29 (4.51%) | |
| Darolutamide | 22 (3.42%) | |
| Ribociclib | 20 (3.11%) | |
| Eltrombopag Olamine | 16 (2.49%) | |
| Decitabine-Cedazuridine | 15 (2.33%) | |
| Ruxolitinib Phosphate | 15 (2.33%) | |
| Abemaciclib | 13 (2.02%) | |
| Asciminib HCl | 13 (2.02%) | |
| Lenvatinib | 13 (2.02%) | |
| Palbociclib | 12 (1.87%) | |
| Zanubrutinib | 12 (1.87%) | |
| Belumosudil Mesylate | 8 (1.24%) | |
| Cabozantinib S-Malate | 8 (1.24%) | |
| Capivasertib | 8 (1.24%) | |
| Dasatinib | 8 (1.24%) | |
| PAZOPanib | 8 (1.24%) | |
| Cabozantinib | 7 (1.09%) | |
| Everolimus | 7 (1.09%) | |
| Imatinib Mesylate | 7 (1.09%) | |
| Osimertinib Mesylate | 7 (1.09%) | |
| Enzalutamide | 6 (0.93%) | |
| Lomustine | 6 (0.93%) | |
| Momelotinib Dihydrochloride | 6 (0.93%) | |
| Nirogacestat | 6 (0.93%) | |
| Pirtobrutinib | 6 (0.93%) | |
| Acalabrutinib | 5 (0.78%) | |
| Adagrasib | 5 (0.78%) | |
| Deferasirox | 5 (0.78%) | |
| Ropeginterferon alfa-2b-njft | 5 (0.78%) | |
| Trifluridine-Tipiracil | 5 (0.78%) | |
| Axitinib | 4 (0.62%) | |
| Belzutifan | 4 (0.62%) | |
| cycloPHOSphamide | 4 (0.62%) | |
| Encorafenib | 4 (0.62%) | |
| Lorlatinib | 4 (0.62%) | |
| PONATinib HCl | 4 (0.62%) | |
| SUNItinib Malate | 4 (0.62%) | |
| Trametinib Dimethyl Sulfoxide | 4 (0.62%) | |
| Vorasidenib | 4 (0.62%) | |
| Apalutamide | 3 (0.47%) | |
| Binimetinib | 3 (0.47%) | |
| Dabrafenib Mesylate | 3 (0.47%) | |
| Deferiprone | 3 (0.47%) | |
| Ivosidenib | 3 (0.47%) | |
| Ixazomib Citrate | 3 (0.47%) | |
| Olaparib | 3 (0.47%) | |
| Tivozanib HCl | 3 (0.47%) | |
| Tretinoin | 3 (0.47%) | |
| Alectinib HCl | 2 (0.31%) | |
| azaCITIDine | 2 (0.31%) | |
| Bosutinib | 2 (0.31%) | |
| Brigatinib | 2 (0.31%) | |
| Cyclophosphamide | 2 (0.31%) | |
| Erlotinib | 2 (0.31%) | |
| Ibrutinib | 2 (0.31%) | |
| Lazertinib Mesylate | 2 (0.31%) | |
| Midostaurin | 2 (0.31%) | |
| Olutasidenib | 2 (0.31%) | |
| Procarbazine HCl | 2 (0.31%) | |
| Repotrectinib | 2 (0.31%) | |
| Revumenib Citrate | 2 (0.31%) | |
| Ripretinib | 2 (0.31%) | |
| Adalimumab | 1 (0.16%) | |
| Alectinib | 1 (0.16%) | |
| Alpelisib | 1 (0.16%) | |
| Anakinra | 1 (0.16%) | |
| Crizotinib | 1 (0.16%) | |
| Enasidenib Mesylate | 1 (0.16%) | |
| Fostamatinib Disodium | 1 (0.16%) | |
| Futibatinib (20 MG Daily Dose) | 1 (0.16%) | |
| Gilteritinib Fumarate | 1 (0.16%) | |
| Inavolisib | 1 (0.16%) | |
| Larotrectinib Sulfate | 1 (0.16%) | |
| Lenvatinib (4 MG Daily Dose) | 1 (0.16%) | |
| Leuprolide Acetate | 1 (0.16%) | |
| Neratinib | 1 (0.16%) | |
| Pacritinib Citrate | 1 (0.16%) | |
| Selinexor (60 MG Once Weekly) | 1 (0.16%) | |
| SORAfenib Tosylate | 1 (0.16%) | |
| Sotorasib Tosylate | 1 (0.16%) | |
| Telotristat | 1 (0.16%) | |
| Tucatinib | 1 (0.16%) | |
| 1 643 medications among 578 patients | ||
4.3 ASAP
| Characteristic1 | N1 | N = 2351 |
|---|---|---|
| Medication | 235 | |
| Dupilumab | 167 (71.1%) | |
| Omalizumab | 42 (17.9%) | |
| Tezepelumab-ekko | 14 (5.96%) | |
| Mepolizumab | 6 (2.55%) | |
| Benralizumab | 3 (1.28%) | |
| Peanut Powder-dnfp Starter Pak | 2 (0.85%) | |
| Peanut | 1 (0.43%) | |
| 1 235 medications among 234 patients | ||
4.4 Dermatology
| Characteristic1 | N1 | N = 2531 |
|---|---|---|
| Medication | 253 | |
| Dupilumab | 111 (43.9%) | |
| Risankizumab-rzaa | 34 (13.4%) | |
| Adalimumab | 21 (8.30%) | |
| Secukinumab | 15 (5.93%) | |
| Apremilast | 14 (5.53%) | |
| Ixekizumab | 8 (3.16%) | |
| Tralokinumab-ldrm | 8 (3.16%) | |
| Upadacitinib | 6 (2.37%) | |
| Upadacitinib ER | 6 (2.37%) | |
| Ustekinumab | 6 (2.37%) | |
| Deucravacitinib | 4 (1.58%) | |
| Etanercept | 4 (1.58%) | |
| Guselkumab | 4 (1.58%) | |
| Ritlecitinib Tosylate | 3 (1.19%) | |
| Baricitinib | 2 (0.79%) | |
| Bexarotene | 2 (0.79%) | |
| Bimekizumab-bkzx | 2 (0.79%) | |
| Golimumab | 1 (0.40%) | |
| Lebrikizumab-lbkz | 1 (0.40%) | |
| Spesolimab-sbzo | 1 (0.40%) | |
| 1 253 medications among 252 patients | ||
5 Observed outcome summaries
5.1 Neurology
| Characteristic | Did not dicontinue within 90 days N = 1401 |
Discontinued within 90 days N = 361 |
|---|---|---|
| Age at date counseled | ||
| Mean (SD) | 63 (18) | 64 (20) |
| Median (Q1, Q3) | 67 (54, 75) | 69 (60, 76) |
| Min, Max | 0, 88 | 6, 92 |
| Race | ||
| White | 111 (79.3%) | 29 (20.7%) |
| Black or African American | 20 (87.0%) | 3 (13.0%) |
| Other | 8 (80.0%) | 2 (20.0%) |
| Unknown | 1 (33.3%) | 2 (66.7%) |
| Sex | ||
| Male | 81 (80.2%) | 20 (19.8%) |
| Female | 59 (78.7%) | 16 (21.3%) |
| Medication | ||
| Droxidopa | 38 (79.2%) | 10 (20.8%) |
| Pimavanserin | 13 (68.4%) | 6 (31.6%) |
| Edaravone | 13 (81.3%) | 3 (18.8%) |
| Cannabidiol | 10 (76.9%) | 3 (23.1%) |
| Riluzole | 11 (100.0%) | 0 (0%) |
| Deutetrabenazine | 9 (90.0%) | 1 (10.0%) |
| Tafamidis | 8 (88.9%) | 1 (11.1%) |
| Valbenazine | 5 (62.5%) | 3 (37.5%) |
| Acoramidis | 7 (100.0%) | 0 (0%) |
| Eplontersen Sodium | 6 (85.7%) | 1 (14.3%) |
| Amantadine | 5 (83.3%) | 1 (16.7%) |
| Amantadine HCl ER | 4 (66.7%) | 2 (33.3%) |
| Deutetrabenazine ER | 5 (83.3%) | 1 (16.7%) |
| Tetrabenazine | 3 (60.0%) | 2 (40.0%) |
| Istradefylline | 1 (50.0%) | 1 (50.0%) |
| Vigabatrin | 2 (100.0%) | 0 (0%) |
| Adalimumab | 0 (0%) | 1 (100.0%) |
| 1 n (%) | ||
5.2 Oncology
| Characteristic | Did not dicontinue within 90 days N = 5051 |
Discontinued within 90 days N = 1381 |
|---|---|---|
| Age at date counseled | ||
| Mean (SD) | 63 (15) | 64 (15) |
| Median (Q1, Q3) | 67 (55, 74) | 68 (55, 75) |
| Min, Max | 18, 92 | 16, 88 |
| Race | ||
| White | 432 (78.5%) | 118 (21.5%) |
| Black or African American | 49 (77.8%) | 14 (22.2%) |
| Other | 17 (81.0%) | 4 (19.0%) |
| Unknown | 7 (77.8%) | 2 (22.2%) |
| Sex | ||
| Male | 316 (82.1%) | 69 (17.9%) |
| Female | 189 (73.3%) | 69 (26.7%) |
| Medication | ||
| Relugolix | 115 (96.6%) | 4 (3.36%) |
| Capecitabine | 28 (70.0%) | 12 (30.0%) |
| Abiraterone Acetate | 32 (86.5%) | 5 (13.5%) |
| Temozolomide | 28 (84.8%) | 5 (15.2%) |
| Venetoclax | 18 (62.1%) | 11 (37.9%) |
| Darolutamide | 20 (90.9%) | 2 (9.09%) |
| Ribociclib | 18 (90.0%) | 2 (10.0%) |
| Eltrombopag Olamine | 8 (50.0%) | 8 (50.0%) |
| Decitabine-Cedazuridine | 9 (60.0%) | 6 (40.0%) |
| Ruxolitinib Phosphate | 15 (100.0%) | 0 (0%) |
| Abemaciclib | 12 (92.3%) | 1 (7.69%) |
| Asciminib HCl | 10 (76.9%) | 3 (23.1%) |
| Lenvatinib | 8 (61.5%) | 5 (38.5%) |
| Palbociclib | 10 (83.3%) | 2 (16.7%) |
| Zanubrutinib | 8 (66.7%) | 4 (33.3%) |
| Belumosudil Mesylate | 8 (100.0%) | 0 (0%) |
| Cabozantinib S-Malate | 4 (50.0%) | 4 (50.0%) |
| Capivasertib | 4 (50.0%) | 4 (50.0%) |
| Dasatinib | 6 (75.0%) | 2 (25.0%) |
| PAZOPanib | 4 (50.0%) | 4 (50.0%) |
| Cabozantinib | 4 (57.1%) | 3 (42.9%) |
| Everolimus | 4 (57.1%) | 3 (42.9%) |
| Imatinib Mesylate | 4 (57.1%) | 3 (42.9%) |
| Osimertinib Mesylate | 6 (85.7%) | 1 (14.3%) |
| Enzalutamide | 5 (83.3%) | 1 (16.7%) |
| Lomustine | 4 (66.7%) | 2 (33.3%) |
| Momelotinib Dihydrochloride | 6 (100.0%) | 0 (0%) |
| Nirogacestat | 5 (83.3%) | 1 (16.7%) |
| Pirtobrutinib | 6 (100.0%) | 0 (0%) |
| Acalabrutinib | 5 (100.0%) | 0 (0%) |
| Adagrasib | 2 (40.0%) | 3 (60.0%) |
| Deferasirox | 4 (80.0%) | 1 (20.0%) |
| Ropeginterferon alfa-2b-njft | 5 (100.0%) | 0 (0%) |
| Trifluridine-Tipiracil | 1 (20.0%) | 4 (80.0%) |
| Axitinib | 4 (100.0%) | 0 (0%) |
| Belzutifan | 3 (75.0%) | 1 (25.0%) |
| cycloPHOSphamide | 3 (75.0%) | 1 (25.0%) |
| Encorafenib | 3 (75.0%) | 1 (25.0%) |
| Lorlatinib | 4 (100.0%) | 0 (0%) |
| PONATinib HCl | 3 (75.0%) | 1 (25.0%) |
| SUNItinib Malate | 2 (50.0%) | 2 (50.0%) |
| Trametinib Dimethyl Sulfoxide | 3 (75.0%) | 1 (25.0%) |
| Vorasidenib | 4 (100.0%) | 0 (0%) |
| Apalutamide | 2 (66.7%) | 1 (33.3%) |
| Binimetinib | 2 (66.7%) | 1 (33.3%) |
| Dabrafenib Mesylate | 2 (66.7%) | 1 (33.3%) |
| Deferiprone | 2 (66.7%) | 1 (33.3%) |
| Ivosidenib | 2 (66.7%) | 1 (33.3%) |
| Ixazomib Citrate | 3 (100.0%) | 0 (0%) |
| Olaparib | 1 (33.3%) | 2 (66.7%) |
| Tivozanib HCl | 2 (66.7%) | 1 (33.3%) |
| Tretinoin | 2 (66.7%) | 1 (33.3%) |
| Alectinib HCl | 2 (100.0%) | 0 (0%) |
| azaCITIDine | 1 (50.0%) | 1 (50.0%) |
| Bosutinib | 2 (100.0%) | 0 (0%) |
| Brigatinib | 2 (100.0%) | 0 (0%) |
| Cyclophosphamide | 1 (50.0%) | 1 (50.0%) |
| Erlotinib | 0 (0%) | 2 (100.0%) |
| Ibrutinib | 0 (0%) | 2 (100.0%) |
| Lazertinib Mesylate | 1 (50.0%) | 1 (50.0%) |
| Midostaurin | 1 (50.0%) | 1 (50.0%) |
| Olutasidenib | 1 (50.0%) | 1 (50.0%) |
| Procarbazine HCl | 1 (50.0%) | 1 (50.0%) |
| Repotrectinib | 2 (100.0%) | 0 (0%) |
| Revumenib Citrate | 2 (100.0%) | 0 (0%) |
| Ripretinib | 1 (50.0%) | 1 (50.0%) |
| Adalimumab | 1 (100.0%) | 0 (0%) |
| Alectinib | 1 (100.0%) | 0 (0%) |
| Alpelisib | 1 (100.0%) | 0 (0%) |
| Anakinra | 0 (0%) | 1 (100.0%) |
| Crizotinib | 1 (100.0%) | 0 (0%) |
| Enasidenib Mesylate | 1 (100.0%) | 0 (0%) |
| Fostamatinib Disodium | 1 (100.0%) | 0 (0%) |
| Futibatinib (20 MG Daily Dose) | 0 (0%) | 1 (100.0%) |
| Gilteritinib Fumarate | 1 (100.0%) | 0 (0%) |
| Inavolisib | 1 (100.0%) | 0 (0%) |
| Larotrectinib Sulfate | 1 (100.0%) | 0 (0%) |
| Lenvatinib (4 MG Daily Dose) | 1 (100.0%) | 0 (0%) |
| Leuprolide Acetate | 1 (100.0%) | 0 (0%) |
| Neratinib | 0 (0%) | 1 (100.0%) |
| Pacritinib Citrate | 1 (100.0%) | 0 (0%) |
| Selinexor (60 MG Once Weekly) | 0 (0%) | 1 (100.0%) |
| SORAfenib Tosylate | 1 (100.0%) | 0 (0%) |
| Sotorasib Tosylate | 1 (100.0%) | 0 (0%) |
| Telotristat | 1 (100.0%) | 0 (0%) |
| Tucatinib | 0 (0%) | 1 (100.0%) |
| 1 n (%) | ||
5.3 ASAP
| Characteristic | PDC greater than or equal to 90 N = 1421 |
PDC less than 90 N = 931 |
|---|---|---|
| Age at date counseled | ||
| Mean (SD) | 43 (26) | 32 (24) |
| Median (Q1, Q3) | 46 (15, 66) | 28 (9, 54) |
| Min, Max | 3, 92 | 1, 79 |
| Race | ||
| White | 104 (61.9%) | 64 (38.1%) |
| Black or African American | 24 (58.5%) | 17 (41.5%) |
| Other | 6 (40.0%) | 9 (60.0%) |
| Unknown | 8 (72.7%) | 3 (27.3%) |
| Sex | ||
| Female | 87 (59.6%) | 59 (40.4%) |
| Male | 55 (61.8%) | 34 (38.2%) |
| Medication | ||
| Dupilumab | 101 (60.5%) | 66 (39.5%) |
| Omalizumab | 25 (59.5%) | 17 (40.5%) |
| Tezepelumab-ekko | 8 (57.1%) | 6 (42.9%) |
| Mepolizumab | 4 (66.7%) | 2 (33.3%) |
| Benralizumab | 1 (33.3%) | 2 (66.7%) |
| Peanut Powder-dnfp Starter Pak | 2 (100.0%) | 0 (0%) |
| Peanut | 1 (100.0%) | 0 (0%) |
| 1 n (%) | ||
| Characteristic | At least 1 gap > 28 days N = 441 |
No gaps > 28 days N = 1911 |
|---|---|---|
| Age at date counseled | ||
| Mean (SD) | 35 (24) | 39 (26) |
| Median (Q1, Q3) | 39 (12, 56) | 41 (12, 65) |
| Min, Max | 1, 78 | 1, 92 |
| Race | ||
| White | 26 (15.5%) | 142 (84.5%) |
| Black or African American | 11 (26.8%) | 30 (73.2%) |
| Other | 5 (33.3%) | 10 (66.7%) |
| Unknown | 2 (18.2%) | 9 (81.8%) |
| Sex | ||
| Female | 29 (19.9%) | 117 (80.1%) |
| Male | 15 (16.9%) | 74 (83.1%) |
| Medication | ||
| Dupilumab | 33 (19.8%) | 134 (80.2%) |
| Omalizumab | 7 (16.7%) | 35 (83.3%) |
| Tezepelumab-ekko | 2 (14.3%) | 12 (85.7%) |
| Mepolizumab | 1 (16.7%) | 5 (83.3%) |
| Benralizumab | 1 (33.3%) | 2 (66.7%) |
| Peanut Powder-dnfp Starter Pak | 0 (0%) | 2 (100.0%) |
| Peanut | 0 (0%) | 1 (100.0%) |
| 1 n (%) | ||
5.4 Dermatology
| Characteristic | PDC greater than or equal to 90 N = 1831 |
PDC less than 90 N = 701 |
|---|---|---|
| Age at date counseled | ||
| Mean (SD) | 48 (20) | 41 (23) |
| Median (Q1, Q3) | 49 (33, 65) | 43 (23, 61) |
| Min, Max | 5, 92 | 1, 85 |
| Race | ||
| White | 138 (75.8%) | 44 (24.2%) |
| Black or African American | 23 (59.0%) | 16 (41.0%) |
| Unknown | 10 (58.8%) | 7 (41.2%) |
| Other | 12 (80.0%) | 3 (20.0%) |
| Sex | ||
| Female | 112 (72.7%) | 42 (27.3%) |
| Male | 70 (71.4%) | 28 (28.6%) |
| Unknown | 1 (100.0%) | 0 (0%) |
| Medication | ||
| Dupilumab | 73 (65.8%) | 38 (34.2%) |
| Risankizumab-rzaa | 32 (94.1%) | 2 (5.88%) |
| Adalimumab | 15 (71.4%) | 6 (28.6%) |
| Secukinumab | 13 (86.7%) | 2 (13.3%) |
| Apremilast | 7 (50.0%) | 7 (50.0%) |
| Ixekizumab | 7 (87.5%) | 1 (12.5%) |
| Tralokinumab-ldrm | 4 (50.0%) | 4 (50.0%) |
| Upadacitinib | 4 (66.7%) | 2 (33.3%) |
| Upadacitinib ER | 5 (83.3%) | 1 (16.7%) |
| Ustekinumab | 6 (100.0%) | 0 (0%) |
| Deucravacitinib | 3 (75.0%) | 1 (25.0%) |
| Etanercept | 3 (75.0%) | 1 (25.0%) |
| Guselkumab | 4 (100.0%) | 0 (0%) |
| Ritlecitinib Tosylate | 1 (33.3%) | 2 (66.7%) |
| Baricitinib | 2 (100.0%) | 0 (0%) |
| Bexarotene | 1 (50.0%) | 1 (50.0%) |
| Bimekizumab-bkzx | 0 (0%) | 2 (100.0%) |
| Golimumab | 1 (100.0%) | 0 (0%) |
| Lebrikizumab-lbkz | 1 (100.0%) | 0 (0%) |
| Spesolimab-sbzo | 1 (100.0%) | 0 (0%) |
| 1 n (%) | ||
| Characteristic | At least 1 gap > 28 days N = 491 |
No gaps > 28 days N = 2041 |
|---|---|---|
| Age at date counseled | ||
| Mean (SD) | 40 (24) | 48 (20) |
| Median (Q1, Q3) | 37 (23, 62) | 49 (33, 64) |
| Min, Max | 1, 85 | 1, 92 |
| Race | ||
| White | 28 (15.4%) | 154 (84.6%) |
| Black or African American | 12 (30.8%) | 27 (69.2%) |
| Unknown | 6 (35.3%) | 11 (64.7%) |
| Other | 3 (20.0%) | 12 (80.0%) |
| Sex | ||
| Female | 29 (18.8%) | 125 (81.2%) |
| Male | 20 (20.4%) | 78 (79.6%) |
| Unknown | 0 (0%) | 1 (100.0%) |
| Medication | ||
| Dupilumab | 29 (26.1%) | 82 (73.9%) |
| Risankizumab-rzaa | 1 (2.94%) | 33 (97.1%) |
| Adalimumab | 5 (23.8%) | 16 (76.2%) |
| Secukinumab | 2 (13.3%) | 13 (86.7%) |
| Apremilast | 3 (21.4%) | 11 (78.6%) |
| Ixekizumab | 1 (12.5%) | 7 (87.5%) |
| Tralokinumab-ldrm | 3 (37.5%) | 5 (62.5%) |
| Upadacitinib | 1 (16.7%) | 5 (83.3%) |
| Upadacitinib ER | 1 (16.7%) | 5 (83.3%) |
| Ustekinumab | 0 (0%) | 6 (100.0%) |
| Deucravacitinib | 0 (0%) | 4 (100.0%) |
| Etanercept | 0 (0%) | 4 (100.0%) |
| Guselkumab | 0 (0%) | 4 (100.0%) |
| Ritlecitinib Tosylate | 1 (33.3%) | 2 (66.7%) |
| Baricitinib | 0 (0%) | 2 (100.0%) |
| Bexarotene | 1 (50.0%) | 1 (50.0%) |
| Bimekizumab-bkzx | 1 (50.0%) | 1 (50.0%) |
| Golimumab | 0 (0%) | 1 (100.0%) |
| Lebrikizumab-lbkz | 0 (0%) | 1 (100.0%) |
| Spesolimab-sbzo | 0 (0%) | 1 (100.0%) |
| 1 n (%) | ||
6 Pharmacist predictions
6.1 Neurology
| Characteristic | N = 1761 |
|---|---|
| Would you be surprised if this patient discontinued this medication in the next 90 days? | |
| Yes | 146 (83.0%) |
| No | 30 (17.0%) |
| Did this patient discontinue this medictaion? | |
| No | 122 (69.3%) |
| Yes | 54 (30.7%) |
| Did this patient discontinue this medication within the next 90 days? | |
| No | 140 (79.5%) |
| Yes | 36 (20.5%) |
| 1 n (%) | |
Sensitivity: 15/36 = 0.42
Specificity: 125/140 = 0.89
PPV: 15/30 = 0.50
NPV: 125/146 = 0.86
Accuracy: 140/176 = 0.80
| Characteristic | Would be surprised (did not predict disc.) N = 1461 |
Would not be surprised (predicted disc.) N = 301 |
|---|---|---|
| Did this patient discontinue this medication within the next 90 days? | ||
| No | 125 (85.6%) | 15 (50.0%) |
| Yes | 21 (14.4%) | 15 (50.0%) |
| 1 n (%) | ||
| Characteristic | Would be surprised (did not predict disc.) N = 211 |
Would not be surprised (predicted disc.) N = 151 |
|---|---|---|
| Reason for discontinuation | ||
| Side effect or adverse drug event | 10 (47.6%) | 9 (60.0%) |
| Patient Deceased | 6 (28.6%) | 1 (6.67%) |
| No/suboptimal response to therapy or disease progression | 3 (14.3%) | 2 (13.3%) |
| Patient decision | 0 (0%) | 2 (13.3%) |
| Administration issues | 1 (4.76%) | 0 (0%) |
| Disease state improvement | 0 (0%) | 1 (6.67%) |
| Medication hold >60 days | 1 (4.76%) | 0 (0%) |
| 1 n (%) | ||
| Characteristic | Would be surprised (did not predict disc.) N = 211 |
Would not be surprised (predicted disc.) N = 151 |
|---|---|---|
| Medication | ||
| Droxidopa | 7 (33.3%) | 3 (20.0%) |
| Pimavanserin | 4 (19.0%) | 2 (13.3%) |
| Cannabidiol | 2 (9.52%) | 1 (6.67%) |
| Edaravone | 2 (9.52%) | 1 (6.67%) |
| Valbenazine | 1 (4.76%) | 2 (13.3%) |
| Amantadine HCl ER | 2 (9.52%) | 0 (0%) |
| Tetrabenazine | 0 (0%) | 2 (13.3%) |
| Adalimumab | 0 (0%) | 1 (6.67%) |
| Amantadine | 0 (0%) | 1 (6.67%) |
| Deutetrabenazine | 0 (0%) | 1 (6.67%) |
| Deutetrabenazine ER | 1 (4.76%) | 0 (0%) |
| Eplontersen Sodium | 1 (4.76%) | 0 (0%) |
| Istradefylline | 0 (0%) | 1 (6.67%) |
| Tafamidis | 1 (4.76%) | 0 (0%) |
| 1 n (%) | ||
6.2 Oncology
| Characteristic | N | N = 6431 |
|---|---|---|
| Would you be surprised if this patient discontinued this medication in the next 90 days? | 643 | |
| Yes | 555 (86.3%) | |
| No | 88 (13.7%) | |
| Did this patient discontinue this medictaion? | 643 | |
| No | 388 (60.3%) | |
| Yes | 255 (39.7%) | |
| Did this patient discontinue this medication within the next 90 days? | 643 | |
| No | 505 (78.5%) | |
| Yes | 138 (21.5%) | |
| 1 n (%) | ||
Sensitivity : 39/138 = 0.28
Specificity : 456/505 = 0.90
PPV: 39/88 = 0.44
NPV: 456/555 = 0.82
Accuracy: 495/643 = 0.77
| Characteristic | Would be surprised (did not predict disc.) N = 5551 |
Would not be surprised (predicted disc.) N = 881 |
|---|---|---|
| Did this patient discontinue this medication within the next 90 days? | ||
| No | 456 (82.2%) | 49 (55.7%) |
| Yes | 99 (17.8%) | 39 (44.3%) |
| 1 n (%) | ||
| Characteristic | Would be surprised (did not predict disc.) N = 991 |
Would not be surprised (predicted disc.) N = 391 |
|---|---|---|
| Reason for discontinuation | ||
| Side effect or adverse drug event | 30 (30.3%) | 11 (28.2%) |
| No/suboptimal response to therapy or disease progression | 31 (31.3%) | 9 (23.1%) |
| Patient Deceased | 11 (11.1%) | 8 (20.5%) |
| Patient decision | 7 (7.07%) | 4 (10.3%) |
| Full course of therapy completed | 7 (7.07%) | 2 (5.13%) |
| Medication hold >60 days | 6 (6.06%) | 2 (5.13%) |
| Provider decision | 5 (5.05%) | 0 (0%) |
| Non-compliance | 0 (0%) | 3 (7.69%) |
| Insurance mandate | 1 (1.01%) | 0 (0%) |
| Lost to follow-up | 1 (1.01%) | 0 (0%) |
| 1 n (%) | ||
| Characteristic | Would be surprised (did not predict disc.) N = 991 |
Would not be surprised (predicted disc.) N = 391 |
|---|---|---|
| Medication | ||
| Capecitabine | 7 (7.07%) | 5 (12.8%) |
| Venetoclax | 8 (8.08%) | 3 (7.69%) |
| Eltrombopag Olamine | 8 (8.08%) | 0 (0%) |
| Decitabine-Cedazuridine | 5 (5.05%) | 1 (2.56%) |
| Abiraterone Acetate | 5 (5.05%) | 0 (0%) |
| Lenvatinib | 4 (4.04%) | 1 (2.56%) |
| Temozolomide | 5 (5.05%) | 0 (0%) |
| Cabozantinib S-Malate | 2 (2.02%) | 2 (5.13%) |
| Capivasertib | 3 (3.03%) | 1 (2.56%) |
| PAZOPanib | 2 (2.02%) | 2 (5.13%) |
| Relugolix | 4 (4.04%) | 0 (0%) |
| Trifluridine-Tipiracil | 2 (2.02%) | 2 (5.13%) |
| Zanubrutinib | 4 (4.04%) | 0 (0%) |
| Adagrasib | 1 (1.01%) | 2 (5.13%) |
| Asciminib HCl | 3 (3.03%) | 0 (0%) |
| Cabozantinib | 2 (2.02%) | 1 (2.56%) |
| Everolimus | 1 (1.01%) | 2 (5.13%) |
| Imatinib Mesylate | 1 (1.01%) | 2 (5.13%) |
| Darolutamide | 1 (1.01%) | 1 (2.56%) |
| Dasatinib | 2 (2.02%) | 0 (0%) |
| Erlotinib | 2 (2.02%) | 0 (0%) |
| Ibrutinib | 2 (2.02%) | 0 (0%) |
| Lomustine | 1 (1.01%) | 1 (2.56%) |
| Olaparib | 1 (1.01%) | 1 (2.56%) |
| Palbociclib | 1 (1.01%) | 1 (2.56%) |
| Ribociclib | 2 (2.02%) | 0 (0%) |
| SUNItinib Malate | 0 (0%) | 2 (5.13%) |
| Abemaciclib | 0 (0%) | 1 (2.56%) |
| Anakinra | 1 (1.01%) | 0 (0%) |
| Apalutamide | 0 (0%) | 1 (2.56%) |
| azaCITIDine | 1 (1.01%) | 0 (0%) |
| Belzutifan | 1 (1.01%) | 0 (0%) |
| Binimetinib | 1 (1.01%) | 0 (0%) |
| cycloPHOSphamide | 1 (1.01%) | 0 (0%) |
| Cyclophosphamide | 0 (0%) | 1 (2.56%) |
| Dabrafenib Mesylate | 0 (0%) | 1 (2.56%) |
| Deferasirox | 1 (1.01%) | 0 (0%) |
| Deferiprone | 1 (1.01%) | 0 (0%) |
| Encorafenib | 1 (1.01%) | 0 (0%) |
| Enzalutamide | 1 (1.01%) | 0 (0%) |
| Futibatinib (20 MG Daily Dose) | 1 (1.01%) | 0 (0%) |
| Ivosidenib | 1 (1.01%) | 0 (0%) |
| Lazertinib Mesylate | 1 (1.01%) | 0 (0%) |
| Midostaurin | 1 (1.01%) | 0 (0%) |
| Neratinib | 0 (0%) | 1 (2.56%) |
| Nirogacestat | 0 (0%) | 1 (2.56%) |
| Olutasidenib | 1 (1.01%) | 0 (0%) |
| Osimertinib Mesylate | 1 (1.01%) | 0 (0%) |
| PONATinib HCl | 1 (1.01%) | 0 (0%) |
| Procarbazine HCl | 1 (1.01%) | 0 (0%) |
| Ripretinib | 1 (1.01%) | 0 (0%) |
| Selinexor (60 MG Once Weekly) | 0 (0%) | 1 (2.56%) |
| Tivozanib HCl | 1 (1.01%) | 0 (0%) |
| Trametinib Dimethyl Sulfoxide | 0 (0%) | 1 (2.56%) |
| Tretinoin | 0 (0%) | 1 (2.56%) |
| Tucatinib | 1 (1.01%) | 0 (0%) |
| 1 n (%) | ||
6.3 ASAP
| Characteristic | N = 2351 |
|---|---|
| Would you be surprised if this patient had a PDC of less than 90 or dose interruptions totaling 28 days or more over the next 6 months? | |
| No | 30 (12.8%) |
| Yes | 205 (87.2%) |
| Did the patient have a PDC of less than 90 or dose interruptions totaling 28 days or more over the 6 month follow-up? | |
| No | 142 (60.4%) |
| Yes | 93 (39.6%) |
| Did the patient have a PDC of less than 90 | |
| No | 142 (60.4%) |
| Yes | 93 (39.6%) |
| Did the patient have at least 1 dose interruption totaling 28 days or more? | |
| No | 191 (81.3%) |
| Yes | 44 (18.7%) |
| 6 month PDC | |
| Mean (SD) | 0.87 (0.16) |
| Median (Q1, Q3) | 0.93 (0.81, 0.99) |
| Min, Max | 0.19, 1.00 |
| 1 n (%) | |
Sensitivity : 14/93 = 0.15
Specificity : 126/142 = 0.89
PPV: 14/30 = 0.47
NPV: 126/205 = 0.61
Accuracy: 140/235 = 0.60
| Characteristic | Would be surprised (did not predict low adh.) N = 2051 |
Would not be surprised (predicted low adh.) N = 301 |
|---|---|---|
| Did the patient have a PDC of less than 90 or dose interruptions totaling 28 days or more over the 6 month follow-up? | ||
| No | 126 (61.5%) | 16 (53.3%) |
| Yes | 79 (38.5%) | 14 (46.7%) |
| 1 n (%) | ||
| Characteristic | PDC greater than or equal to 90 N = 1421 |
PDC less than 90 N = 931 |
|---|---|---|
| Would be surprised (did not predict low adh.) | ||
| Yes | 126 (88.7%) | 79 (84.9%) |
| No | 16 (11.3%) | 14 (15.1%) |
| 1 n (%) | ||
| Characteristic | PDC greater than or equal to 90 N = 1421 |
PDC less than 90 N = 931 |
|---|---|---|
| Medication | ||
| Dupilumab | 101 (71.1%) | 66 (71.0%) |
| Omalizumab | 25 (17.6%) | 17 (18.3%) |
| Tezepelumab-ekko | 8 (5.63%) | 6 (6.45%) |
| Mepolizumab | 4 (2.82%) | 2 (2.15%) |
| Benralizumab | 1 (0.70%) | 2 (2.15%) |
| Peanut Powder-dnfp Starter Pak | 2 (1.41%) | 0 (0%) |
| Peanut | 1 (0.70%) | 0 (0%) |
| 1 n (%) | ||
6.4 Dermatology
| Characteristic | N = 2531 |
|---|---|
| Would you be surprised if this patient had a PDC of less than 90 or dose interruptions totaling 28 days or more over the next 6 months? | |
| No | 42 (16.6%) |
| Yes | 211 (83.4%) |
| Did the patient have a PDC of less than 90 or dose interruptions totaling 28 days or more over the 6 month follow-up? | |
| No | 183 (72.3%) |
| Yes | 70 (27.7%) |
| Did the patient have a PDC of less than 90 | |
| No | 183 (72.3%) |
| Yes | 70 (27.7%) |
| Did the patient have at least 1 dose interruption totaling 28 days or more? | |
| No | 204 (80.6%) |
| Yes | 49 (19.4%) |
| 6 month PDC | |
| Mean (SD) | 0.89 (0.16) |
| Median (Q1, Q3) | 0.97 (0.86, 1.00) |
| Min, Max | 0.31, 1.00 |
| 1 n (%) | |
Sensitivity : 15/70 = 0.21
Specificity : 156/183 = 0.85
PPV: 15/42 = 0.36
NPV: 156/211 = 0.74
Accuracy: 171/253 = 0.68
| Characteristic | Would be surprised (did not predict low adh.) N = 2111 |
Would not be surprised (predicted low adh.) N = 421 |
|---|---|---|
| Did the patient have a PDC of less than 90 or dose interruptions totaling 28 days or more over the 6 month follow-up? | ||
| No | 156 (73.9%) | 27 (64.3%) |
| Yes | 55 (26.1%) | 15 (35.7%) |
| 1 n (%) | ||
| Characteristic | PDC greater than or equal to 90 N = 1831 |
PDC less than 90 N = 701 |
|---|---|---|
| Would be surprised (did not predict low adh.) | ||
| Yes | 156 (85.2%) | 55 (78.6%) |
| No | 27 (14.8%) | 15 (21.4%) |
| 1 n (%) | ||
| Characteristic | PDC greater than or equal to 90 N = 1831 |
PDC less than 90 N = 701 |
|---|---|---|
| Medication | ||
| Dupilumab | 73 (39.9%) | 38 (54.3%) |
| Risankizumab-rzaa | 32 (17.5%) | 2 (2.86%) |
| Adalimumab | 15 (8.20%) | 6 (8.57%) |
| Secukinumab | 13 (7.10%) | 2 (2.86%) |
| Apremilast | 7 (3.83%) | 7 (10.0%) |
| Ixekizumab | 7 (3.83%) | 1 (1.43%) |
| Tralokinumab-ldrm | 4 (2.19%) | 4 (5.71%) |
| Upadacitinib | 4 (2.19%) | 2 (2.86%) |
| Upadacitinib ER | 5 (2.73%) | 1 (1.43%) |
| Ustekinumab | 6 (3.28%) | 0 (0%) |
| Deucravacitinib | 3 (1.64%) | 1 (1.43%) |
| Etanercept | 3 (1.64%) | 1 (1.43%) |
| Guselkumab | 4 (2.19%) | 0 (0%) |
| Ritlecitinib Tosylate | 1 (0.55%) | 2 (2.86%) |
| Baricitinib | 2 (1.09%) | 0 (0%) |
| Bexarotene | 1 (0.55%) | 1 (1.43%) |
| Bimekizumab-bkzx | 0 (0%) | 2 (2.86%) |
| Golimumab | 1 (0.55%) | 0 (0%) |
| Lebrikizumab-lbkz | 1 (0.55%) | 0 (0%) |
| Spesolimab-sbzo | 1 (0.55%) | 0 (0%) |
| 1 n (%) | ||